Diagnostic accuracy of methylated SEPT9 for blood-based colorectal cancer detection: A systematic review and meta-analysis

Clinical and Translational Gastroenterology

Volumn 8, Issue 1, 2017, Pages

  Nian, Jiayun ^a,b   Sun, Xu ^a   Ming, Su Yang ^c   Yan, Chen ^a,b   Ma, Yunfei ^a   Feng, Ying ^b   Yang, Lin ^a   Yu, Mingwei ^a   Zhang, Ganlin ^a   Wang, Xiaomin ^a  

^a BEIJING HOSPITAL OF TRADITIONAL CHINESE MEDICINE AFFILIATED TO CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SEPTIN; SEPTIN 9; UNCLASSIFIED DRUG;

CANCER STAGING; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL POLYP; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; PRECANCER; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUMOR DIFFERENTIATION;

EID: 85036637362     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2016.66     Document Type: Review

References (41)

1. Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. Cancer J Clin 2015; 65: 87-108.
2. Edwards BK, Ward E, Kohler BA et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010; 116: 544-573.
3. Meester RG, Doubeni CA, Zauber AG et al. Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. Cancer 2015; 121: 2281-2285.
4. Fedewa SA, Sauer AG, Siegel RL et al. Prevalence of major risk factors and use of screening tests for cancer in the United States. Cancer Epidemiol Biomarkers Prev 2015; 24: 637-652.
5. Jones RM, Devers KJ, Kuzel AJ et al. Patient reported barriers to colorectal cancer screening: a mixed-methods analysis. Am J Prev Med 2010; 38: 508-516.
6. Lieberman DA. Clinical practice. Screening for colorectal cancer. N Engl J Med 2009; 361: 1179-1187.
7. Pratt VM. Are we ready for a blood-based test to detect colon cancer? Clin Chem 2014; 60: 1141-1142.
8. Tariq K, Ghias K. Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med 2016; 13: 120-135.
9. Lofton-Day C, Model F, Devos T et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 2008; 54: 414-423.
10. Hall PA, Russell SE. The pathobiology of the Septin gene family. J Pathol 2004; 204: 489-505.
11. Warren JD, Xiong W, Bunker AM et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med 2011; 9: 133.
12. Tóth K, Sipos F, Kalmár A et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS One 2012; 7: e46000.
13. deVos T, Tetzner R, Model F et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 2009; 55: 1337-1346.
14. Church TR, Wandell M, Lofton-Day C et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014; 63: 317-325.
15. Whiting PF, Rutjes AW, Westwood ME et al. QUADAS-2 Group QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155: 529-536.
16. Johnson DA, Barclay RL, Mergener K et al. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PLoS One 2014; 9: e98238.
17. Tóth K, Wasserkort R, Sipos F et al. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cellfree DNA. PLoS One 2014; 9: e115415.
18. Lee HS, Hwang SM, Kim TS et al. Circulating methylated septin 9 nucleic Acid in the plasma of patients with gastrointestinal cancer in the stomach and colon. Transl Oncol 2013; 6: 290-296.
19. Perez-Carbonell L, Balaguer F, Toiyama Y et al. IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer. PLoS One 2014; 9: e104285.
20. Grützmann R, Molnar B, Pilarsky C et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 2008; 3: e3759.
21. Tänzer M, Balluff B, Distler J et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One 2010; 5: e9061.
22. Su XL, Wang YF, Li SJ et al. High methylation of the SEPT9 gene in Chinese colorectal cancer patients. Genet Mol Res 2014; 13: 2513-2520.
23. Potter NT, Hurban P, White MN et al. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clin Chem 2014; 60: 1183-1191.
24. He Q, Chen HY, Bai EQ et al. Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer. Cancer Genet Cytogene 2010; 202: 1-10.
25. Wu D, Zhou G, Jin P et al. Detection of colorectal cancer using a simplified SEPT9 gene methylation assay is a reliable method for opportunistic screening. J Mol Diagn 2016; 18: 535-545.
26. Ahlquist DA, Taylor WR, Mahoney DW et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol 2012; 10: 272-277.
27. Orntoft MB, Nielsen HJ, Orntoft TF et al. Danish Study Group on Early Detection of Colorectal Cancer. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study. BMC Cancer 2015; 15: 819.
28. Yu D, Zhang XH, Lu XX. Study on diagnostic value of SEPT9 gene methylation in serum for colorectal cancer. Chin J Chin Lab Sci 2015; 33: 687-689.
29. Jin P. Role of Mismatch Repair Protein in Estradiol-induced Colon Cancer Cells Apoptosis and Performance of Methylated SPET9 Test in Detecting Colorectal Neoplasm. Chongqing: Third Military Medical University. 2015.
30. He Q, Wang M, Zhou JW et al. Detection of ALX4 and SEPT9 methylation in human colorectal cancer by Multiplex MethyLight assay. J Sun Yat-Sen Univ (Med Sci) 2015; 36: 657-662.
31. He N. The Study on the Application Value of Serum Methylated SEPT9 for Optimizing Screening Scheme of Colorectal Cancer. Fourth Military Medical University: Xi'an, China, 2015.
32. Wang Z, Chen JC, He Q et al. MS-HRM detecting free methylation SEPT9 in early diagnosis of colorectal cancer. Guangdong Med J 2012; 33: 1732-1734.
33. Li SJ, Liu YG, Wang J et al. The study of peripheral methylation SEPT9 in screening colorectal cancer. Chin J Gen Surg 2015; 124: 1756-1760.
34. Kang J, Jin P, Yang L et al. The study of methylation SEPT9 in peripheral DNA for colorectal cancer screening. Natl Med J China 2014; 94: 3839-3841.
35. Ding QQ, Zhang H, Xu HC et al. Study of methylation SEPT9 for colorectal cancer screening in aged population. Chin J Geriatr 2015; 34: 1348-1350.
36. Bibbins-Domingo K, Grossman DC, Curry SJ et al. US Preventive Services Task Force Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2016;315:2564-2575.
37. Li Y, Song L, Gong Y et al. Detection of colorectal cancer by DNA methylation biomarker SEPT9: past, present and future. Biomark Med 2014; 8: 755-769.
38. Premarket approval (PMA) for Epi proColon.US Food and Drug Administration. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfmid=P130001. Accessed 21 April 2016.
39. Tetzner R, Dietrich D, Distler J. Control of carry-over contamination for PCR-based DNA methylation quantification using bisulfite treated DNA. Nucleic Acids Res 2007; 35: e4.
40. Adler A, Geiger S, Keil A et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol 2014; 14: 183.
41. Tham C, Chew M, Soong R et al. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer. Cancer 2014; 120: 3131-3141.